Syndax Pharmaceuticals News

Syndax Pharmaceuticals (SNDX) Gets a Buy From Stifel Nicolaus

TipRanksMay 12 21:07

Citigroup Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $30

Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $32 to $30.

BenzingaMay 9 12:52

Syndax Pharmaceuticals Price Target Raised to $40.00/Share From $39.00 by Stifel

Syndax Pharmaceuticals Price Target Raised to $40.00/Share From $39.00 by Stifel

Dow JonesMay 9 09:15

Syndax Pharmaceuticals Is Maintained at Buy by Stifel

Syndax Pharmaceuticals Is Maintained at Buy by Stifel

Dow JonesMay 9 09:15

Stifel: Maintaining the Syndax Pharmaceuticals (SNDX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $39.00 to $40.00.

Stifel: Maintaining the Syndax Pharmaceuticals (SNDX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $39.00 to $40.00.

Zhitong FinanceMay 9 09:10

Syndax Announces Participation at the Bank of America Securities 2024 Health Care Conference

Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...

PR NewswireMay 9 06:00

Buy Rating for Syndax Pharmaceuticals Amid Strong Financials and Promising Drug Candidate

TipRanksMay 9 05:27

Analysts' Top Healthcare Picks: Elanco Animal Health (ELAN), Syndax Pharmaceuticals (SNDX)

TipRanksMay 9 04:31

Syndax Pharmaceuticals Q1 Net Loss Widens

Syndax Pharmaceuticals (SNDX) reported a Q1 net loss Wednesday of $0.85 per diluted share, wider than a loss of $0.59 a year earlier. Analysts polled by Capital IQ expected a loss of $0.97. The compan

MT NewswiresMay 8 08:22

Syndax Pharmaceuticals Q1 2024 GAAP EPS $(0.85) Beats $(0.99) Estimate

Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.85) per share which beat the analyst consensus estimate of $(0.99) by 14.14 percent. This is a 44.07 percent decrease over losses

BenzingaMay 8 06:17

Syndax Pharmaceuticals | 10-Q: Quarterly report

Futu NewsMay 8 06:08 · Announcements

Syndax Pharmaceuticals 1Q Loss $72.4M >SNDX

Syndax Pharmaceuticals 1Q Loss $72.4M >SNDX

Dow JonesMay 8 06:06

Syndax Pharmaceuticals 1Q Loss/Shr 85c >SNDX

Syndax Pharmaceuticals 1Q Loss/Shr 85c >SNDX

Dow JonesMay 8 06:06

Analysts' Opinions Are Mixed on These Healthcare Stocks: Addus Homecare (ADUS), BioCryst (BCRX) and Syndax Pharmaceuticals (SNDX)

TipRanksMay 7 07:21

HC Wainwright & Co. : The Syndax Pharmaceuticals (SNDX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $41.00.

HC Wainwright & Co. : The Syndax Pharmaceuticals (SNDX.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $41.00.

Zhitong FinanceApr 26 06:40

Buy Rating Reaffirmed for Syndax Pharmaceuticals on Strong Drug Pipeline and Strategic Partnerships

TipRanksApr 26 05:15

Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum

Syndax Pharmaceuticals (NASDAQ:SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a fireside chat at the at Stifel 2024 Virtual Targeted Oncology Forum on Wednesday, April 17, 2024, at 11:00 a.m. ET.

PRNewswireApr 10 15:05

Analysts Offer Insights on Healthcare Companies: Syndax Pharmaceuticals (SNDX), Inozyme Pharma (INZY) and PTC Therapeutics (PTCT)

TipRanksApr 9 04:40

Analysts Are Bullish on Top Healthcare Stocks: Syndax Pharmaceuticals (SNDX), Legend Biotech (LEGN)

TipRanksApr 8 18:50

Buy Rating Affirmed for Syndax Pharmaceuticals Amidst Strong Clinical Results and Strategic Growth Prospects

TipRanksApr 8 10:35